One half of J&J’s treatment is Lazcluze, a pill that, like Astra’s Tagrisso, blocks a cancer-associated protein called EGFR.
The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...
The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
Zacks Investment Research on MSN15h
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to SobiIonis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...
A array of startups whose technology ranges from bleeding edge healthcare solutions to wildfire risk assessment have been ...
Founders at the University of Cambridge welcomes eight new startups to the START Accelerator 2.0 programme, powering growth ...
We recently published a list of the 12 Best AI Stocks to Invest in According to Reddit. In this article, we are going to take ...
Vadym Popko is a professor of the Department of Comparative and European Law of the Educational and Research Institute of ...
Safeguards Of Dapagliflozin's Half Billion USD Sales In China: Astrazeneca. Legal News and Analysis - China - Conventus Law ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback